Compare PCLA & EVOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCLA | EVOK |
|---|---|---|
| Founded | 2008 | 2007 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.6M | 18.4M |
| IPO Year | 2025 | 2013 |
| Metric | PCLA | EVOK |
|---|---|---|
| Price | $0.21 | $10.96 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 748.5K | 30.4K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $5,065,197.00 | ★ $14,424,652.00 |
| Revenue This Year | N/A | $58.96 |
| Revenue Next Year | N/A | $57.99 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 5.26 | ★ 67.40 |
| 52 Week Low | $0.25 | $1.94 |
| 52 Week High | $9.80 | $10.99 |
| Indicator | PCLA | EVOK |
|---|---|---|
| Relative Strength Index (RSI) | 19.99 | 84.79 |
| Support Level | $0.27 | $10.66 |
| Resistance Level | $0.33 | $10.99 |
| Average True Range (ATR) | 0.02 | 0.05 |
| MACD | -0.00 | -0.19 |
| Stochastic Oscillator | 7.00 | 89.69 |
PicoCELA Inc specializes in manufacturing, installing, and servicing enterprise wireless mesh solutions. The company generates revenue from two main sources: product equipment sales, and Software as a Service (SaaS) and maintenance services. The company develops the PCWL series of mesh Wi-Fi access points, which utilize its proprietary PicoCELA Backhaul Engine (PBE) technology to enable wireless communication. The company outsources manufacturing and sells these devices directly to customers through distributors. Additionally, the company offers a cloud portal service in a SaaS model, allowing users to monitor connectivity and traffic at their access points. This platform also supports the installation of proprietary edge-computing software into the devices.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.